VLDLR and metabolic dysfunction-associated steatohepatitis: Considering the speedy progression of NASH fibrosis/atherosclerosis and similarities in systemic cholesterol/lipoprotein metabolism and VLDLR expression in macrophages of atherogenic plaques to humans, utilizing this rabbit model would save time to assess NASH fibrosis/atherosclerosis-retarding effects of candidate agents, such as cholesterol-lowering statins and ezetimibe.